Immunosuppressants are essential to maintain transplanted organ survival and functionality, however, overimmunosuppression may lead to serious life-threatening complications such as infection and cancer. Optimal immunosuppression is warranted for the Asian, who are prone to have more infections in post-transplantation settings. However, few studies have focused on the pharmacokinetic profile of immunosuppressants in Asian transplant patients. In the era of precision medicine, individuality based on the pharmacogenomic profile is the target goal of personalized immunosuppression. Moreover, the safety and efficacy profile of generic forms should are understood in the scope of individuality.
Teun Van Gelden
Professor Clinical Pharmacology
Leiden University Medical Center
Dr. Teun van Gelder is an internist-nephrologist and clinical pharmacologist. He was trained in internal medicine and nephrology at the Erasmus Medical Center and completed his thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. As a post-doctoral scientist, he worked in the Transplantation Immunology Laboratory of Dr. Randall E. Morris at Stanford University (1998-2000), and was awarded the Young Investigator Award from the American Society for Transplantation for his work during this time.
Between 2000 and 2019 he worked in the Departments of Hospital Pharmacy and Internal Medicine at the Erasmus Medical Center in Rotterdam, the Netherlands.
In 2010, at Erasmus Medical Center he was appointed Professor in Clinical Pharmacology. His research at the Erasmus Medical Center was focused on clinical pharmacology and therapeutic drug monitoring. He was the chairman of the Dutch Society for Clinical Pharmacology & Biopharmacy, the secretary of the Dutch Society for Transplantation, and the President of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology.
In December 2019 Teun van Gelder accepted a new position in Leiden University Medical Center (LUMC). He was appointed Professor in Drug Discovery & Development. LUMC, Leiden Institute of Chemistry, Leiden Academic Centre for Drug Research (LACDR), Centre for Human Drug Research (CHDR), and Leiden Bio Science Park (LBSP) together have the expertise and facilities for the design, development, and testing of new innovative drugs. This environment is unique in the Netherlands and provides an excellent basis for drug discovery and drug development. In his role as an experienced internist – clinical pharmacologist Teun will make an important contribution to Academic Pharma.
Jong Choel Jeong
Clinical Assistant Professor
Seoul National University Bundang Hospital
Seoul, South Korea
As both a transplant nephrologist and translational researcher, my main interest area is the clinical epidemiologic studies based on post-transplant cohort. I have actively participated Korean Organ Transplantation Registry (KOTRY) project and the Asian Society of Transplantation Registry (ASTREG) project. Both are working as the data platform for solid organ transplantation patients' clinical courses. Recently, my research topics involved tacrolimus metabolism, dominant risk factors of kidney transplantation, and the impact of eplet mismatches. All those publications were based on the development of kidney transplantation cohort.
National Heart Institute
Kuala Lumpur, Malaysia
Welcome and introduction by the Chairs
Presentation: Balances between two sides in immunosuppression: risk of rejection and infectious complications, Teun Van Gelden,The Netherlands
Live Q&A with Teun Van Gelden,The Netherlands
Presentation: Pharmacogenomic studies in Asian kidney transplantation in original and generic immunosuppressants, Jong Choel Jeong, South Korea
Live Q&A with Jong Choel Jeong, South Korea
Interactive panel discussion with audience participation led by the Chairs
Masterclass closing remarks